Scarica l'app Stockscreener
1,027.51
1.80%
18.13
Dopo l'orario di chiusura:
1029.44
1.93
+0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next - ts2.tech
Clinical trials reveal promising results for new Eli Lilly drug - NewsNation
What's Going On With Eli Lilly Stock Friday?Eli Lilly (NYSE:LLY) - Benzinga
Eli Lilly to Build $6-Billion Alabama Facility - AdvancedManufacturing.org
Moody’s affirms Eli Lilly’s Aa3 rating, outlook revised to positive By Investing.com - Investing.com Nigeria
Eli Lilly (LLY) Reports Promising Results from Phase 3 EMBER-3 S - GuruFocus
Eli Lilly announces updated results from Phase 3 EMBER-3 study of Inluriyo - TipRanks
Exclusive: FDA leaders pushed to cut Lilly weight-loss pill review time - Reuters
Lilly shifts ambition for broader oral SERD label to largest oncology trial in company history - Fierce Pharma
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win - Yahoo Finance
Eli Lilly touts strong results of new experimental weight loss drug retatrutide - Straight Arrow News
Eli Lilly Stock Rises After Late-Stage Data Shows Longer Survival With Breast Cancer Drug - Stocktwits
U.S. Regulators Pushed to Fast-Track Approval of Eli Lilly’s (LLY) Weight-Loss Pill: Reports - TipRanks
Eli Lilly (LLY) Gains EU Support for Mounjaro Use in Younger Pat - GuruFocus
EU committee backs extending use of Lilly's diabetes drug for children aged 10 and above - Reuters
Lilly's next-gen drug shows greater weight loss than Zepbound in late-stage trial - Reuters
Truist Securities reiterates Buy rating on Eli Lilly stock at $1,182 - Investing.com
Lilly to Invest $6B in New API Manufacturing Facility in Alabama - Contract Pharma
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025) - ts2.tech
US FDA likely to speed up evaluation of Eli Lilly's weight loss pill - medwatch.com
Eli Lilly (LLY) Boosts Dividend by 15.3% - GuruFocus
FDA May Fast-Track Eli Lilly’s Weight Loss PillEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly & Co: Promising Future with Strong TRIUMPH-4 Trial Results and Strategic Pipeline Driving Growth - TipRanks
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Dec 2025) - 24/7 Wall St.
Eli Lilly (LLY) Pushes for Faster FDA Review of Weight Loss Pill - GuruFocus
Think Eli Lilly is expensive? This metric says otherwise. - MSN
Top FDA brass said to have pushed for a faster review of Lilly’s weight loss pill - Seeking Alpha
Think Eli Lilly Is Expensive? This Metric Says Otherwise. - The Motley Fool
Exclusive-US FDA brass pushed internally for speedier Lilly weight-loss pill verdict - Yahoo
Lilly CEO talks innovation, ‘generational impact’ ahead of 150th anniversary - Inside INdiana Business
Eli Lilly to build $6 B worth API manufacturing facility in US - BioSpectrum Asia
A Decade of Rewards: $47 Bil From Eli Lilly Stock - Trefis
Lilly’s next-gen drug tops Zepbound on weight loss in late-stage trial - WHTC
Eli Lilly's Retatrutide Shows 28.7% Weight Loss in Phase 3 Trial - 조선일보
Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments - The Daily Upside
Eli Lilly Drug for 3 Obesity Targets Sets New High Bar for Weight Loss in a Clinical Trial - MedCity News
Pharmaceutical giant Lilly plans $6 billion advanced manufacturing plant in Huntsville, Alabama - Alabama Weather Network
Eli Lilly's $6B boost: New jobs, growth for Huntsville-Limestone County area - WAAY 31 News
Lilly’s Retatrutide Raises Weight-Loss Bar In First Phase III Readout - Citeline News & Insights
Eli Lilly's $6 billion boost means new jobs, growth for Huntsville-Limestone County area - WAAY 31 News
Eli Lilly's $6B boost: new jobs, growth for Limestone County - WAAY 31 News
Eli Lilly's next-gen obesity drug shows biggest weight loss yet in clinical trial - AOL.com
Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open - ts2.tech
Eli Lilly Puts Obesity Field 'On Notice' With Best Weight Loss - Investor's Business Daily
Stock Movers: Mosaic Company, Eli Lilly, Lululemon - Bloomberg.com
New Eli Lilly Drug Retatrutide Brought Major Weight Loss in Trial - The New York Times
S&P 500 Slips as Oracle’s AI Capex Shock Knocks Wind Out of Post-Fed Rally - Investing.com
Eli Lilly Reveals $6B Pharmaceutical Facility in Alabama - Thomasnet
Stock Movers: Eli Lilly, Gemini Space Station, Oracle - Bloomberg.com
Eli Lilly Says Trial of Weight-Loss Drug Retatrutide Yields Encouraging Results - marketscreener.com
Eli Lilly's (LLY) Retatrutide Surpasses Expectations in Weight L - GuruFocus
Premarket Movers Thursday Oracle Stock Drops Eli Lilly Surges Amazon Under Pressure - TECHi
Market Voices: Lilly's new obesity drug, Bessent, EQT's robotics move - Seeking Alpha
Eli Lilly’s Adverum Acquisition: What They Didn’t Say in the Press Release! - Smartkarma
Eli Lilly’s Weight Loss Superdrug Worked So Well During Trials, Some Quit Over Losing Too Much - Gizmodo
A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds - The Independent
Eli Lilly Stock Rises After New Obesity Drug Crushes Phase 3 Goa - GuruFocus
Eli Lilly Stock Rises After New Obesity Drug Crushes Phase 3 Goals - TradingView
Eli Lilly (LLY) Stock Is Up, What You Need To Know - Finviz
Eli Lilly (LLY) Shares Surge on Promising Retatrutide Phase 3 Re - GuruFocus
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial - MSN
Lilly rises on “best-in-class” data for new weight loss therapy - Seeking Alpha
Lilly to build $6B weight-loss drug factory in Alabama - Manufacturing Dive
Eli Lilly’s (LLY) Newest Weight-Loss Drug Delivers Strong Results in Late-Stage Trial - TipRanks
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial - PharmExec.com
Major weight loss, pain relief seen with Eli Lilly's next-gen drug in late-stage trial - Fox Business
0.75%
0.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):